Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   42567   clinical trials with a EudraCT protocol, of which   7008   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2009-013091-40
    Sponsor's Protocol Code Number:M10-444
    National Competent Authority:Czechia - SUKL
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2010-02-23
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedCzechia - SUKL
    A.2EudraCT number2009-013091-40
    A.3Full title of the trial
    Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg with Active Juvenile Idiopathic Arthritis (JIA)
    A.4.1Sponsor's protocol code numberM10-444
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAbbVie Deutschland GmbH & Co. KG
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAbbVie Inc.
    B.4.2CountryCzech Republic
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAbbVie Ltd.
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D. name Humira
    D. of the Marketing Authorisation holderAbbott Laboratories Limited
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAdalimumab
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNADALIMUMAB
    D.3.9.1CAS number 331731-18-1
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product Information not present in EudraCT
    D. ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D. on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Juvenile Idiopathic Arthritis (JIA)
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10059176
    E.1.2Term Juvenile idiopathic arthritis
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate the safety of adalimumab in subjects 2 to < 4 years of age and subjects age 4 and above that weigh < 15 kg with moderately to severely active polyarticular JIA or polyarticular course JIA.
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are to collect PK data and to evaluate the efficacy of adalimumab in Subjects 2 to < 4 years of age and subjects age 4 and above that weigh < 15 kg with moderately to severely active polyarticular JIA or polyarticular course JIA.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Pharmacokinetic samples will be obtained from a sub-section of subjects after informed consent for this sub-study has been obtained. Refer section of the protocol for further details.
    E.3Principal inclusion criteria
    1. A parent or guardian has voluntarily signed and dated an informed consent form,
    approved by an Institutional Review Board (IRB)/Independent Ethics Committee
    (IEC), after the nature of the study has been explained and the subject's parent or
    legal guardian has had the opportunity to ask questions. The informed consent
    must be signed before any study-specific procedures are performed or before any
    medication is discontinued for the purpose of this study.
    2. Subject has a disease diagnosis of moderate to severe active polyarticular or
    polyarticular course JIA (defined as arthritis affecting ≥ 5 joints at the time of
    treatment initiation). This corresponds to the International League of Associations
    for Rheumatology (ILAR: Appendix C) categories of polyarticular rheumatoid
    factor positive (RF+), and polyarticular Rheumatoid factor negative (RF-) disease.
    3. Subject must be aged 2 to < 4 years old with moderately to severely active
    polyarticular JIA or polyarticular course JIA or age 4 or greater weighing < 15 kg
    with moderately to severely active polyarticular JIA or polyarticular course JIA,
    per ILAR criteria.
    4. Subject is judged to be in generally good health as determined by the Investigator
    based upon the results of medical history, laboratory profile, and physical
    examination performed at Screening and confirmed at Baseline. This includes, but
    is not limited to, a normal cardiopulmonary and normal neurological exam result.
    5. Parent or legal guardian must be able and willing to administer subcutaneous (SC)
    injections or have a qualified person available to administer SC injections.
    6. Parent or legal guardian must be willing to actively supervise storage and
    administration of study drug and to ensure that the time of each dose is accurately
    recorded in the subject's diary.
    7. Subject must have negative PPD test (or equivalent) at Screening. If subject has a
    positive PPD test result, a chest X-ray (PA and lateral view) must be performed. Ifsubject has a positive test (or equivalent), has had a post ulcerative reaction to PPD placement, and/or a chest X-ray consistent with TB exposure, subject must have
    documented completion of course of anti-TB therapy.
    E.4Principal exclusion criteria
    1. Subject has had prior exposure to Tysabri® (natalizumab) or any other biologic
    therapy, such as Orencia® (abatacept). Any previous use of anti-TNF agents,
    including Etanercept (Enbrel®), Infliximab (Remicade®), certolizumab pegol,
    golimumab, and adalimumab is also prohibited.
    2. Subject has undergone joint surgery within the preceding two months of the
    Screening Visit (at joints to be assessed within the study).
    3. Subject has a previous diagnosis of a condition that could cause arthritis other than polyarticular JIA.
    4. Subject has a history of an allergic reaction or significant sensitivity to constituents
    of the study drug, adalimumab.
    5. Subject has been treated with any investigational biologic agents (e.g., Kineret®
    (anakinra) and Rituxan (rituximab). Should these biologics become approved,
    they would continue to be excluded.
    6. Subject has a poorly controlled medical condition, such as uncontrolled diabetes,
    unstable heart disease, recent cerebrovascular accidents, seizure disorder, and any
    other condition which, in the opinion of the Investigator, would put the subject at
    risk by participation in the study.
    7. Subject has a history of clinically significant hematologic (e.g., severe anemia,
    leukopenia, thrombocytopenia, a clotting disorder), renal, liver disease
    (e.g., fibrosis, cirrhosis, hepatitis), or active gastroenteric ulcer.
    8. Subject is known to have any acquired immune deficiency (i.e., HIV infection) or
    untreated congenital immunodeficiency. Abbott Study-Designated Physician
    approval required for specific congenital immunodeficiency cases.
    9. Subject is considered by the Investigator, for any reason, to be an
    unsuitable candidate for the study.
    10. Subject has evidence of active TB infection.
    11. Subject has history of moderate to severe congestive heart failure (NYHA class III
    or IV), recent cerebrovascular accident or thrombotic event and any other
    condition which, in the opinion of the investigator, would put the subject at risk by
    participation in the protocol.
    12. History of CNS demyelinating disease or neurologic symptoms suggestive of CNS
    demyelinating disease.
    13. History of listeriosis, histoplasmosis, chronic or active Hepatitis B infection,
    human immunodeficiency virus (HIV) infection, immunodeficiency syndrome,
    chronic recurring infections or active TB.
    E.5 End points
    E.5.1Primary end point(s)
    The primary study endpoint, measured over the course of the study is the incidence rate of serious adverse events (SAEs) and adverse events (AEs) in polyarticular JIA Subjects 2 to < 4 years old and Subjects 4 years and above weighing less than 15 kg.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    In section 13 of the protocol the end of the trial is defined as the date of the last subject's last scheduled visit or the actual date of follow-up contact, whichever is longer.

    The purpose of the follow-up period is to collect additional safety information.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    A parent or guardian will provide consent for the child
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state1
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 10
    F.4.2.2In the whole clinical trial 30
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    At the conclusion of the trial the subject's physician will review the subject's current status together with the subject's parents or guardian and determine the best course of action. If a market authorization for subjects 4 to 13 years old has been approved in the EU, the physician may choose to continue to treat the subject with commercial adalimumab. Humira is expected to be commercially available by Q2 2011 for use in children 4 - 13 years of age.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2010-05-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2010-02-03
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2013-03-21
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice